MEA Metabolomics Market

MEA Metabolomics Market Size (2023 to 2028)

The Middle East and Africa Metabolomics Market size have been estimated at USD 328.12 Million in 2023. It is further estimated to grow at a CAGR of 25% from 2023 and worth USD 1001.35 Million by 2028.

Metabolomics is the significant scale research of little molecules, generally known as metabolites, inside cells, biofluids, tissues, or living beings. Metabolomics is a proficient approach since metabolites and their concentration, not like other "omics" measures, straightforwardly reflect the unseen biochemical movement and tissues' condition. Consequently, metabolomics signifies atomic phenotype. Aggregately, these little atoms and their associations inside an organic framework are known as the metabolome.

The emerging recognition of metabolomics in customized medicines is one of the key factors boosting the market's growth. The expanding biotech innovative work and pharmaceutical consumption prompt persistent headways in innovation, spelling development for the worldwide metabolomics market. The unexplored markets in rising countries will goad new development open doors for market players. Further, the requirement for precisely qualified specialists and the lack of the same is limiting the expansion of the metabolomics market. The Middle East and Africa's Metabolomics market are evolving at a rapid speed.

This research report on the Middle East and Africa Metabolomics Market has been segmented and sub-segmented into the following categories:

By Product: 

• GC
• Bioinformatics
• Mass Spectrometry
• HPLC
• UPLC
• NMRS
• Surface-based mass analysis

By Indication: 

• Oncology
• Cardiology
• Inborn Error

By Application: 

• Nutrigenomics
• Toxicology
• Biomarker 
• Drug Discovery

By Country: 

• KSA
• UAE
• Israel
• the rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA       

Based on Application, the Biomarker Discovery segment had the largest share in 2018 in the global metabolomics market. Efficiency and reliability have been cited as the reason for the growth of biomarkers. However, a collaboration between biotechnology and pharmaceutical companies, the personalized medical segment is expected to have the highest CAGR.

Based on the region, the Middle East and Africa have an untapped market, and key players are slowly expanding to this region, which is the main reason for the market's growth in this region.

Key Companies leading the Middle East & Africa Metabolomics Market profiled in this report are Agilent Technologies, Inc. (U.S.), Human Metabolome Technologies, Inc. (Japan), Thermo Fisher Scientific, Inc. (U.S.), LECO Corporation (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), Metabolon Inc. (U.S.), Danaher Corporation (U.S.), Biocrates Life Sciences AG (Austria), and Waters Corporation (U.S.).